Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 3/20 | 0.50 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.46 |
| ▸ | PDE7A | Q13946 | 6/20 | 0.40 |
| ▸ | SPR | P35270 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.37 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.37 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.37 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 5/20 | 0.36 |
| ▸ | KDR | P35968 | 5/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.35 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.35 |
| ▸ | MERTK | Q12866 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19657320 | 0.85 | CREBBP (0.52) | CREBBPPDE7ASPRKDM4C | |
| SCHEMBL19657312 | 0.84 | CREBBP (0.51) | CREBBPSSTR4PDE7ASPRKDM4C | |
| SCHEMBL22822778 | 0.78 | CREBBP (0.48) | CREBBPSSTR4 | |
| SCHEMBL21024056 | 0.74 | CREBBP (0.38) | CREBBPSSTR4 | |
| SCHEMBL19644534 | 0.71 | CNR2 (0.46) | CREBBPSSTR4PDE7ASPRKDM4C | |
| SCHEMBL29704358 | 0.71 | CNR2 (0.46) | CREBBPSSTR4PDE7ASPRKDM4C | |
| SCHEMBL19657665 | 0.68 | CREBBP (0.48) | CREBBPPDE7ASPR | |
| SCHEMBL23135543 | 0.66 | KAT2B (0.42) | CREBBP | |
| SCHEMBL31195590 | 0.65 | SPR (0.43) | CREBBPSSTR4SPRKDM4CTEAD1 | |
| SCHEMBL34460387 | 0.65 | SPR (0.43) | CREBBPSSTR4SPRKDM4CTEAD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168070-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200399244-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399244-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC3 | CREBBP 7/4885SSTR4 4484/4885PDE7A 3532/4885 |
| US-11168070-B2 | Therapeutic compounds and uses thereof | EP300, HDAC1, HDAC11 | CREBBP 6/4885SSTR4 4514/4885PDE7A 3455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.